Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the vesting of share options granted in 2006 under the GlaxoSmithKline Share Option Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity compensation vesting details rather than consolidated financial performance.
Material Changes and Vesting Details
The filing details the outcome of the three-year performance period (January 1, 2006, to December 31, 2008) for share options granted in 2006 at an option price of £14.68 (US$51.02 for ADSs).
- Performance-Based Grants: For Executive Directors and CET members, performance conditions were not fully met. Consequently, the Remuneration Committee confirmed that only 50.7% of the original grant was exercisable.
- Non-Performance-Based Grants: For senior executives appointed as Executive Directors or CET members after the 2006 grant, awards were not subject to performance conditions. The Remuneration Committee confirmed that 100% of the original grant was exercisable.
| Executive / CET Member | Shares Exercisable | ADSs Exercisable | Grant Type |
|---|---|---|---|
| Mr A P Witty (Executive Director) | 89,993 | - | Performance-Based (50.7%) |
| Mr J S Heslop (Executive Director) | 117,117 | - | Performance-Based (50.7%) |
| Mr J M Clarke | 89,993 | - | Performance-Based (50.7%) |
| Mr M Dunoyer | 35,490 | - | Performance-Based (50.7%) |
| Mr D J Phelan | - | 44,997 | Performance-Based (50.7%) |
| Mr D Pulman | - | 29,153 | Performance-Based (50.7%) |
| Dr M Slaoui (Executive Director) | 68,520 | - | Non-Performance-Based (100%) |
| Mr S M Bicknell | 12,650 | - | Non-Performance-Based (100%) |
| Mr E J Gray | 26,800 | - | Non-Performance-Based (100%) |
| Mr D Learmouth | 12,650 | - | Non-Performance-Based (100%) |
| Mr D S Redfern | 26,800 | - | Non-Performance-Based (100%) |
| Ms C Thomas | 20,180 | - | Non-Performance-Based (100%) |
| Mr J R Stephenne | 68,520 | - | Non-Performance-Based (100%) |
| Mr W C Louv | 11,870 | - | Non-Performance-Based (100%) |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on business strategy, or specific risk factors. The document is a regulatory notification of past compensation vesting events.
Key Facts for Investor Verification
- Verify the impact of the 50.7% vesting rate on the total equity compensation expense for the 2006 grant cohort.
- Confirm the distinction between performance-based grants (Executive Directors/CET members) and non-performance-based grants (senior executives appointed later).
- Review the specific performance conditions that were not fully met during the 2006-2008 period to understand the company's operational targets.
- Check subsequent filings for the actual exercise of these options and the resulting dilution or cash inflow.